Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis
- PMID: 36695377
- DOI: 10.1016/j.jtha.2022.10.022
Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis
Abstract
Disseminated intravascular coagulation (DIC) is a life-threatening complication in sepsis and other critical conditions. The International Society on Thrombosis and Haemostasis (ISTH) released the diagnostic criteria for overt DIC in 2001. Since then, ISTH overt DIC has been used as the global standard criterion for a decompensated stage of DIC. Because detecting an earlier stage of DIC would be useful for therapeutic considerations, the scientific standardization committees of the ISTH introduced the sepsis-induced coagulopathy (SIC) scoring system in 2019. The SIC scoring system is specifically designed to detect the compensated phase of DIC in sepsis, which can lead to overt DIC with disease progression. Studies examining the performance of the SIC scoring system have reported its usefulness over the past 5 years. The reported incidence of SIC was approximately 60% in patients with sepsis, which was twice as much as that of overt DIC. Almost all patients with overt DIC were diagnosed with SIC earlier. The reported mortality of SIC was ≥30% and, thus, can be used for patient selection for anticoagulant therapy. Despite the limited data, some continue to suggest the potential efficacy of anticoagulant therapy in patients with SIC. Although heparin, antithrombin, and thrombomodulin are the candidates for anticoagulation, none of them have proven to be effective with robust evidence, and future trials are warranted.
Keywords: anticoagulants; anticoagulation; coagulopathy; diagnostic criteria; disseminated intravascular coagulation; prothrombin time; sepsis.
Copyright © 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest T. Iba participated on the advisory boards of Japan Blood Products Organization, Asahi Kasei Pharmaceuticals, and Toray Medical. M. Levi has received grants and has participated on the advisory boards of Novo Nordisk, Eli Lilly, Asahi Kasei Pharmaceuticals America, and Johnson & Johnson. J. Helms has received honoraria from Diagnostica Stago, Pfizer PFE France, Sanofi Aventis France, MSD, Shionogi, and Inotrem. J. H. Levy serves on the Steering or Advisory Committees for Instrumentation Laboratories, Merck, Octapharma. E. Scarlatescu has received speaker fees from CSL Behring. J. Thachil has no competing interests to disclose.
Comment in
-
"Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis on sepsis-induced coagulopathy in the management of sepsis": Comment from Wada et al.J Thromb Haemost. 2023 Jun;21(6):1677-1678. doi: 10.1016/j.jtha.2023.02.024. J Thromb Haemost. 2023. PMID: 37179075 No abstract available.
-
"Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis on sepsis-induced coagulopathy in the management of sepsis": reply.J Thromb Haemost. 2023 Jun;21(6):1679-1680. doi: 10.1016/j.jtha.2023.02.025. J Thromb Haemost. 2023. PMID: 37179076 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous